Show simple item record

dc.contributor.authorDodson, Aen_US
dc.contributor.authorOkonji, Den_US
dc.contributor.authorAssersohn, Len_US
dc.contributor.authorRigg, Aen_US
dc.contributor.authorSheri, Aen_US
dc.contributor.authorTurner, Nen_US
dc.contributor.authorSmith, Ien_US
dc.contributor.authorParton, Men_US
dc.contributor.authorDowsett, Men_US
dc.date.accessioned2017-09-15T15:08:45Z
dc.date.issued2018-02en_US
dc.identifier.citationBreast cancer research and treatment, 2018, 168 (1), pp. 249 - 258en_US
dc.identifier.issn0167-6806en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/826
dc.identifier.eissn1573-7217en_US
dc.identifier.doi10.1007/s10549-017-4514-zen_US
dc.description.abstractPURPOSE:Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) breast cancer, produces a recurrence score (RS) related to distant disease recurrence (DR) risk (RS%). In node-negative patients, RS can be integrated with clinicopathological parameters to derive RS-pathology-clinical (RSPC) that improves prognostic accuracy. METHODS:Data were collected on patients having clinically indicated tests with an intermediate clinical risk of distant recurrence, and for whom the decision to prescribe chemotherapy remained unclear. Correlation between RS% and RSPC scores was examined. An agreement table was constructed using risk-categorised data. Association between RS%-derived categorical risk assignments and treatment recommendation was evaluated. RESULTS:Data on 171 tests (168 patients) were available. Median DR risk by RS% was 11% (range 3-34%), by RSPC it was 15% (range 4-63%). Correlation between RS% and RSPC was 0.702 (p < 0.001). RS% classified 57.3% of cases as low-, 32.2% intermediate- and 10.5% high-risk for DR; by RSPC proportions were 33.9, 35.7, and 30.4%, respectively. The number of patients receiving chemotherapy recommendations was: 14/87 (16.1%) categorised as low-risk by RS%, 27/49 (55.1%) as intermediate-risk and 12/13 (92.3%) as high-risk. Of 149 patients recommended for endocrine treatment alone, 28 (18.8%) were categorised by RS% as low-risk but by RSPC as intermediate- or high-risk. CONCLUSIONS:In this group of patients, RSPC assessed fewer patients as low-risk and more as high-risk than did RS%. The discordances between the scores indicate that RSPC estimates of risk should be considered when selecting patients for endocrine therapy alone.en_US
dc.formatPrint-Electronicen_US
dc.format.extent249 - 258en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectBreasten_US
dc.subjectHumansen_US
dc.subjectBreast Neoplasmsen_US
dc.subjectBreast Neoplasms, Maleen_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectReceptors, Estrogenen_US
dc.subjectAntineoplastic Agents, Hormonalen_US
dc.subjectPrognosisen_US
dc.subjectChemotherapy, Adjuvanten_US
dc.subjectMastectomyen_US
dc.subjectIncidenceen_US
dc.subjectRisk Assessmenten_US
dc.subjectPredictive Value of Testsen_US
dc.subjectGene Expression Profilingen_US
dc.subjectPatient Selectionen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectMiddle Ageden_US
dc.subjectFemaleen_US
dc.subjectMaleen_US
dc.subjectGenetic Testingen_US
dc.subjectUnited Kingdomen_US
dc.titleDiscordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-09-13en_US
rioxxterms.funderThe Institute of Cancer Researchen_US
rioxxterms.identifier.projectUnspecifieden_US
rioxxterms.versionofrecord10.1007/s10549-017-4514-zen_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2018-02en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBreast cancer research and treatmenten_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume168en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMolecular Oncologyen_US
icr.researchteamMedicine (RMH Smith Cunningham)en_US
icr.researchteamEndocrinologyen_US
dc.contributor.icrauthorDowsett, Mitchen_US
dc.contributor.icrauthorTurner, Nicholasen_US
dc.contributor.icrauthorSmith, Ianen_US
dc.contributor.icrauthorMarsden,en_US
rioxxterms.funder.project354849bd-c553-4e22-868c-8c503e124155en_US


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record